United Therapeutics Corp. (UTHR) PT Lowered to $271 at JPMorgan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq rise as tech stocks gain ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts UTHR Hot Sheet
Price: $600.64 +0.76%
Rating Summary:
18 Buy, 9 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 12 | Down: 17 | New: 12
Rating Summary:
18 Buy, 9 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 12 | Down: 17 | New: 12
Join SI Premium – FREE
JPMorgan analyst Jessica Fye lowered the price target on United Therapeutics Corp. (NASDAQ: UTHR) to $271.00 (from $280.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Essential Properties Realty Trust (EPRT) PT Lowered to $31 at Cantor Fitzgerald
- Apple (AAPL) PT Raised to $295 at DA Davidson Despite Disappointing Services Growth
- EverQuote (EVER) PT Raised to $35 at Needham
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
